| Mr Scott Alan Ruplin, MSW | |
|
1550 Nw Eastman Pkwy, Gresham, OR 97030-3858 | |
| (503) 571-0725 | |
| Not Available |
| Full Name | Mr Scott Alan Ruplin |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 1550 Nw Eastman Pkwy, Gresham, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417059270 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 3153 (Oregon) | Primary |
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.
Consumer Watchdog called on President Obama and Congress in a letter sent today to fix ten problem areas in the new federal health reform law that, if not addressed, will be exploited by health insurers and drug companies looking to charge more for less health care.
Cytori Therapeutics received expanded European approval (CE Mark) for its Celution System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. The new indications include key medical applications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds, such as those resulting from Crohn's disease. This broadens Cytori's ability to offer the Celution System to patients and hospitals and further supports the company's efforts to gain treatment reimbursement.
In a new report, the Institute of Medicine concludes that raising Medicare reimbursements for some areas of the country will not necessarily address the physician shortage.
A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Scott Alan Ruplin, MSW 1229 Se 19th Ave, Portland, OR 97214-3804 Ph: (503) 880-3026 | Mr Scott Alan Ruplin, MSW 1550 Nw Eastman Pkwy, Gresham, OR 97030-3858 Ph: (503) 571-0725 |
News Archive
Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.
Consumer Watchdog called on President Obama and Congress in a letter sent today to fix ten problem areas in the new federal health reform law that, if not addressed, will be exploited by health insurers and drug companies looking to charge more for less health care.
Cytori Therapeutics received expanded European approval (CE Mark) for its Celution System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. The new indications include key medical applications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds, such as those resulting from Crohn's disease. This broadens Cytori's ability to offer the Celution System to patients and hospitals and further supports the company's efforts to gain treatment reimbursement.
In a new report, the Institute of Medicine concludes that raising Medicare reimbursements for some areas of the country will not necessarily address the physician shortage.
A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.
› Verified 1 days ago
Matthew Joseph Bartolotti, LSCW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 400 Ne 7th St, Gresham, OR 97030 Phone: 503-489-2236 | |
Ryely Wilpone, MSW, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 600 Ne 8th St, Gresham, OR 97030 Phone: 503-988-5155 Fax: 503-988-5185 | |
Jamie Nash-sedda, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2970 Ne 7th St, Gresham, OR 97030 Phone: 509-863-4560 | |
James Macleod, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4101 Ne Division St, Gresham, OR 97030 Phone: 971-284-1963 | |
Alyssa Wirthlin, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 400 Ne 7th St, Gresham, OR 97030 Phone: 503-661-5455 | |
Christen Skolnick, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 24988 Se Stark St Ste 140, Mail Code: Cmng, Gresham, OR 97030 Phone: 971-262-9806 Fax: 971-262-9501 | |
Colette Renee Deleon, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1217 Ne Burnside Rd, Building B Suite 401, Gresham, OR 97030 Phone: 503-666-8832 Fax: 503-669-8641 |